Alexion Pharmaceuticals, Inc. (ALXN) Holdings Increased by Parametric Portfolio Associates LLC

Parametric Portfolio Associates LLC boosted its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 5.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 691,926 shares of the biopharmaceutical company’s stock after buying an additional 37,663 shares during the period. Parametric Portfolio Associates LLC owned about 0.31% of Alexion Pharmaceuticals worth $97,070,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Rathbone Brothers plc increased its holdings in shares of Alexion Pharmaceuticals by 2.5% in the 2nd quarter. Rathbone Brothers plc now owns 2,040 shares of the biopharmaceutical company’s stock valued at $248,000 after purchasing an additional 50 shares during the period. Geneva Advisors LLC increased its holdings in shares of Alexion Pharmaceuticals by 0.7% in the 2nd quarter. Geneva Advisors LLC now owns 11,408 shares of the biopharmaceutical company’s stock valued at $1,388,000 after purchasing an additional 82 shares during the period. Evercore Wealth Management LLC increased its holdings in shares of Alexion Pharmaceuticals by 8.1% in the 2nd quarter. Evercore Wealth Management LLC now owns 1,665 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 125 shares during the period. Wealthsource Partners LLC increased its holdings in shares of Alexion Pharmaceuticals by 4.4% in the 2nd quarter. Wealthsource Partners LLC now owns 3,002 shares of the biopharmaceutical company’s stock valued at $365,000 after purchasing an additional 126 shares during the period. Finally, Penserra Capital Management LLC increased its holdings in shares of Alexion Pharmaceuticals by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 144 shares during the period. Hedge funds and other institutional investors own 94.33% of the company’s stock.

A number of brokerages have recently weighed in on ALXN. Credit Suisse Group reiterated a “buy” rating and issued a $166.00 target price on shares of Alexion Pharmaceuticals in a report on Tuesday, December 12th. Leerink Swann reiterated a “buy” rating and issued a $169.00 target price on shares of Alexion Pharmaceuticals in a report on Wednesday, December 6th. TheStreet downgraded Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, November 10th. Zacks Investment Research downgraded Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. Finally, Royal Bank of Canada increased their price objective on Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $155.47.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $115.76 on Friday. Alexion Pharmaceuticals, Inc. has a twelve month low of $96.18 and a twelve month high of $149.34. The company has a market capitalization of $26,470.00, a P/E ratio of 23.13, a P/E/G ratio of 1.23 and a beta of 1.18. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.32 by $0.12. The firm had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The company’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.23 earnings per share. analysts expect that Alexion Pharmaceuticals, Inc. will post 4.82 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/12/17/alexion-pharmaceuticals-inc-alxn-holdings-increased-by-parametric-portfolio-associates-llc.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply